Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTER-EWING-1 for Ewing sarcoma
ACTRN12624000532505Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- Feb 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of regorafenib, vinorelbine, cyclophosphamide, vincristine, doxorubicin and 2 more in Ewing sarcoma (8 arms), sponsored by University of Birmingham. Primary endpoint: Event-free survival. Started Feb 2024; status: recruiting.
02
Drugs
regorafenibvinorelbinecyclophosphamidevincristinedoxorubicin
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on ACTRN12624000532505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000532505.